{"id":"W4413111668","doi":"10.1016/j.esmoop.2025.105544","title":"Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; Eisai; Daiichi-Sankyo; Arena Pharmaceuticals; G1 Therapeutics; Incyte; Sanofi; Exelixis; Merck KGaA; Gilead Sciences; Ipsen; Mirati Therapeutics; Clovis Oncology; EUSA Pharma; Seagen; Roche; Pfizer; Eli Lilly and Company; AstraZeneca; National Cancer Institute; Accuray","keywords":"Medicine; Pembrolizumab; Internal medicine; Carboplatin; Gemcitabine; Oncology; Metastatic Urothelial Carcinoma; Clinical endpoint; Chemotherapy; Phases of clinical research; Population; Cisplatin; Cancer; Gastroenterology; Bladder cancer; Randomized controlled trial; Urothelial carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01087868,0.001727344,0.00375063,0.0006468108,0.0002812425,0.001018911,0.0008753397,0.001008689,0.002172319],"category_scores_gemma":[0.00587797,0.0004169909,0.008970914,0.0007427439,0.000539163,0.0008118105,0.0008039886,0.001792844,0.0002170037],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006718459,"about_ca_system_score_gemma":0.001166824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000541407,"about_ca_topic_score_gemma":0.002235956,"domain_scores_codex":[0.9954967,0.00326422,0.0002548857,0.0004609459,0.0002503139,0.0002729621],"domain_scores_gemma":[0.9973969,0.001404833,0.0004339098,0.0003796724,0.0001275467,0.0002570504],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8835126,0.001243981,0.01819337,0.001517773,0.05939029,0.0002447748,0.0001585281,0.002392532,0.006574031,0.0002242333,0.001601988,0.02494584],"study_design_scores_gemma":[0.4347131,0.211256,0.1749238,0.00037089,0.1499134,0.0007038901,0.000610958,0.009655915,0.006990894,0.002461046,0.008197964,0.0002020336],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814433,0.01058443,0.001988911,0.0004566668,0.0002606493,0.001479941,0.002557413,0.00008078553,0.001147992],"genre_scores_gemma":[0.9912076,0.001224538,0.001940587,0.0004661577,0.0001476981,0.00171368,0.002532437,0.0000395453,0.0007278018],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01087868,"threshold_uncertainty_score":0.05753267,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06668643470950594,"score_gpt":0.426261484299137,"score_spread":0.359575049589631,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}